Table of Contents

Friday, 03 May 2013

Welcome

13.10 - 13.30

Setting the Scene: Current Status of Surgical and Medical mRCC-Treatment
By: Ronald M. Bukowski, M.D.
Powerpoint  | Video

Pathology and Prognosis

13.30 - 13.45

Pathology of RCC: What do Clinicians Need to Know
By: Holger Moch, M.D.
Powerpoint  | Video

13.45 - 14.00

Rare Metastatic Sites in mRCC: A Different Disease?
By: Gerald Mickisch, M.D.
Powerpoint  | Video

14.00 - 14.15

Depressive Symptoms as Key Predictors of Survival in mRCC
By: Eric Jonasch, M.D.
Powerpoint  | Video

14.15 - 14.30

What Should we Do About Patients with Brain Metastases?
By: Vincent Khoo, M.D.
Powerpoint  | Video

Surgical Aspects of mRCC Treatment

15.10 - 15.20

Debate: Lymphadenectomy is Important in mRCC PRO
By: Christopher G. Wood, M.D., FACS
Powerpoint  | Video

15.20 - 15.30

Debate: Lymphadenectomy is Important in mRCC CON
By: Jean Jacques Patard, M.D.
Powerpoint  | Video

15.30 - 15.40

Small Primary in Metastatic Disease: Is it Worth to be Removed? PRO
By: Gerald Mickisch, M.D.
Powerpoint  | Video

15.40 - 15.50

Small Primary in Metastatic Disease: Is it Worth to be Removed? CON
By: Jean Jacques Patard, M.D.
Powerpoint  | Video

15.50 - 16.00

Surgical Treatment of Atypical Metastases from RCC
By: Nicola Arrighi, M.D.
Powerpoint  | Video

16.00 - 16.15

What Does the Medical Oncologist Expect from the Surgeon Including Case (and Metastasectomy)
By: Manuela Schmidinger, M.D.
Powerpoint  | Video

16.15 - 16.45

Cases Presentation
By: Professor Peter Tenke, M.D.
Powerpoint  | Video

By: Csaba Pustzai, M.D., Ph.D.
Powerpoint  | Video

By: Arnaud Méjean, M.D., Ph.D.
Powerpoint  | Video

 

Saturday, 04 May 2013

Systemic mRCC Treatment (after COMPARZ, PISCES, BevLin and TORAVA...)

08.05 - 08.15

Pazopanib is the Best Choice in First-Line
By: Fabio Calabro, M.D.
Powerpoint  | Video

08.15 - 08.25

Sunitinib Remains the Best Choice in First-Line
By: Camillo Porta, M.D.
Powerpoint  | Video

08.25 - 08.35

Bevacizumab+Low Dose IFN is the Best Choice in First-Line
By: Bohuslav Melichar, M.D.
Powerpoint  | Video

08.35 - 08.45

Will Highly Selective TKIs Become First-Line Standard of Care?
By: Joaquim Bellmunt, M.D.
Powerpoint  | Video

08.45 - 09.00

Second-Line Strategies
By: Viktor Grünwald, M.D.
Powerpoint  | Video

09.00 - 09.25

Case 1: Success in mRCC (with an Unusual Strategy)
By: Sylvie Negrier, M.D., Ph.D.
Powerpoint  | Video

Case 2: Success in mRCC
By: Rosalie Fisher, M.D.
Powerpoint  | Video

The Role of Additional Strategies in mRCC

09.50 - 10.00

The Cytokine-Era is Over: What Should We Do About Sorafenib?
By: James Larkin, Ph.D., MRCP
Powerpoint  | Video

10.00 - 10.10

EGFR-Targeting in mRCC: A Closed Chapter?
By: Alain Ravaud, M.D., Ph.D.
Powerpoint  | Video

10.10 - 10.20

Are Currently Available mTOR-Inhibitors Convincing in mRCC?
By: Tim Eisen, M.D.
Powerpoint  | Video

10.20 - 10.30

Novel Immunotherapeutic Approaches in mRCC
By: David F. McDermott, M.D.
Powerpoint  | Video

Many Open Questions in RCC

10.40 - 10.50

Rationale for Anti-VEGF(R)-Strategies in the Adjuvant Setting: Is There a Target at All?
By: Tim Eisen, M.D.
Powerpoint  | Video

10.50 - 11.00

Management of Papillary Type 2 mRCC and Case and Study
By: Thomas Powles, M.D., MBBS, MRCP
Powerpoint  | Video

11.00 - 11.10

Management of Translocational Tumors and Case and Study
By: Cora N. Sternberg, M.D., FACP
Powerpoint  | Video

11.10 - 11.20

Management of Collecting Duct Carcinoma and Case
By: Emiliano Calvo, M.D., Ph.D.
Powerpoint  | Video

11.20 - 11.30

Strategies Beyond VEGF-Inhibitors and mTOR-Inhibitors
By: Bernard Escudier, M.D.
Powerpoint  | Video

11.30 - 11.40

Case(s): How to Deal with Mixed Response
By: Giuseppe Procopio, M.D.
Powerpoint  | Video

11.55 - 12.30

What can we Expect from Running Phase III Trials:
Will all of Them Alter the Current Treatment Algorithm?
By: Martin Gore, Ph.D., FRCP
Powerpoint  | Video

Challenges From Treatment and From the Disease

14.15 - 14.30

Rare Complications of Systemic mRCC Treatment
By: Sergio Bracarda, M.D.
Powerpoint  | Video

14.30 - 14.45

Inflammation in mRCC: Target or Prognostic Factor?
By: Benoit Beuselinck, M.D.
Powerpoint  | Video

14.45 - 15.00

Management of Chronic Renal Failure Under Anti-VEGF-Directed Treatment
By: Christian Kollmannsberger, M.D.
Powerpoint  | Video

15.00 - 15.15

Metabolic Disorders
By: Paul Nathan, FRCP, Ph.D.
Powerpoint  | Video

15.15 - 15.30

Mechanisms and Management of Diarrhea from Anti-VEGFR-TKIs
By: Manuela Schmidinger, M.D.
Powerpoint  | Video

Long-Term Survival in mRCC

16.10 - 16.20

Complete Remission is a Reachable Goal in mRCC
By: Laurence Albiges, M.D.
Powerpoint  | Video

16.20 - 16.30

mRCC-Favorable Risk Long-Term Survivor: Case 1
By: Cesary Szczylik, M.D.
Powerpoint  | Video

16.30 - 16.40

mRCC Intermediate Risk Long-Term Survivor: Case 2
By: Sylvie Negrier, M.D., Ph.D.
Powerpoint  | Video

16.40 - 16.50

mRCC Poor Risk Long-Term Survivor: Case 3
By: Rosalie Fisher, M.D.
Powerpoint  | Video